Erda-iDRS delivers erdafitinib into the bladder over three months, enabling localised therapy and reducing systemic exposure.

J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as ...

Please provide your email address to receive an email when new articles are posted on . Neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin significantly benefited patients with ...

Colorblindness may be doing more than making traffic lights confusing — it could also be hiding a life-threatening warning ...

Rising case numbers attributed to older population, with overall underlying risk remaining flat or decreasing over the last ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the ...

Investigators sought to determine if the gemcitabine intravesical system plus intravenous cetrelimab could improve survival ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?